Evaluation of cytotoxicity of nanoparticulate materials in porcine kidney cells and human hepatocarcinoma cells.
This chapter describes method for evaluation of nanomaterial cytotoxicity by examining effects on porcine kidney (LLC-PK1) and human cancerous liver cells (Hep G2). Several studies indicate that many nanoparticles are cleared from the body through the kidney or liver, making these organs good choices for target organ toxicity evaluation. In this standard, two separate metrics (MTT and LDH) provide complementary data, that can be used to identify interference.
Nanotechnology Characterization Laboratory, Advanced Technology Program, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, MD, USA.
Timothy M
TM
Potter
Stephan T
ST
Stern
D000818:Animals; D005562:Formazans / Q000032:analysis; D056945:Hep G2 Cells; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D018374:LLC-PK1 Cells; D053758:Nanoparticles / Q000633:toxicity*; D010316:Particle Size; D013050:Spectrometry, Fluorescence; D013552:Swine; D013778:Tetrazolium Salts / Q000032:analysis / Q000378:metabolism
D005562:Formazans; D013778:Tetrazolium Salts; C079782:MTT formazan; D007770:L-Lactate Dehydrogenase